Jump to content
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

BIOPRO BW Logo

Main navigation

  • Start page Start page
  • About us

    About us

    Close Close
    • Team
      • Our authors
    • History and achievements
    • Supervisory Board
    • Career
    • Contact / Travel information
  • Activities

    Activities

    Close Close
    • Start-up support
    • Cooperation initiatives
    • Anlaufstelle Regulatorik Gesundheitswirtschaft BW
  • Projects

    Projects

    Close Close
    • Current projects
      • Forum Health Region Baden-Württemberg
      • Advanced Imaging Utilization by Digital Data Application in Baden-Württemberg (PC3-AIDA)
      • Alliance for sustainable medical technology
      • The Phytopharmaceuticals and Valuable Plant Ingredients initiative
      • PRECISEU - PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope
      • HACK-IT-NET - enabling an alpine region Health And Care Knowledge and Innovation Transfer NETwork
    • General Projects
      • EXI Start-Up Voucher
      • LinkHealth@BW
    • Completed projects
      • MDR & IVDR Fast-Track Support BW
      • Photon-Counting (PC)-CT Consortium
      • Health Data Scenarios
      • Baden-Württemberg-Center for Academic Drug Discovery
      • Post-Brexit
      • MDR & IVDR Competence Centre BW (MIK)
  • Services

    Services

    Close Close
    • Funding
    • Research institutions
    • Healthcare industry database
    • Job market
    • Newsletter
    • Stay in touch with us!
  • Information

    Information

    Close Close
    • Press releases & contact
    • Publications
  • Events

    Events

    Close Close
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Lab-on-a-chip - 11/11/2020 Bild_3.jpg

    Microfluidic platform for the best possible cancer therapy

    Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

    https://www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
  • Dossier - 09/11/2020 Verpackung_Silphie_Faser.jpg

    Packaging of the future

    What will the packaging of the future look like, and what will be required of it? Can packaging be biobased, recyclable, sustainable and economic? In Baden-Württemberg, there are various approaches to developing packaging with the above properties from various sources including agricultural residual and side streams as well as municipal waste.

    https://www.biooekonomie-bw.de/en/articles/dossiers/packaging-future
  • Article - 04/11/2020 Analysegerät und Kartusche

    Rapid coronavirus test delivers results in 43 minutes

    The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.

    https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
  • Inside the fight against COVID-19 - 28/10/2020 Apogenix_Asunercept_COVID-19_Teaser.png

    A new immunotherapeutic agent for treating severe COVID-19 cases

    Apogenix, a Heidelberg-based biopharmaceutical company specialising in innovative immunotherapeutics, has initiated a Phase II clinical trial with asunercept, the company’s lead drug candidate for treating severe cases of COVID-19. The fusion protein blocks the CD95-ligand-mediated death of epithelial cells in the lung and thus prevents damage to the organ.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-immunotherapeutic-agent-treating-severe-covid-19-cases
  • Funding

    European Circular Bioeconomy Fund

    Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investors
    https://www.bio-pro.de/en/database/funding/european-circular-bioeconomy-fund
  • Funding

    European Circular Bioeconomy Fund

    Funding programme, Funded by: European Investment Bank (EIB), European countries/National Promotional Banks, Industry investors, Financial investors
    https://www.biooekonomie-bw.de/en/databases/funding/european-circular-bioeconomy-fund
  • Phosphorus recovery from sewage sludge - 21/10/2020 teaser_1.jpg

    Bacteria help to recycle phosphorus

    Biotechnology for the bioeconomy: in something known as the P-bac process, sulphur bacteria extract phosphorus from sewage sludge ash. Phosphorus is one of the key building blocks of life and an essential nutrient for plant growth. When there is not enough phosphorus in the soil, farmers apply it via organic or mineral fertilisers.

    https://www.biooekonomie-bw.de/en/articles/news/bacteria-help-recycle-phosphorus
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial - with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • KyooBe Tech GmbH - 08/10/2020 Scheme of the patented pump and roll system (LEEI technology).

    Next generation vaccine production

    For decades, conventional inactivated vaccines have been produced by killing pathogens with toxic chemicals. However, this process often changes the surface structure of the pathogens to such an extent that the immune system is only able to induce a weak response. KyooBe Tech GmbH is offering a method that uses low-energy electrons to inactivate pathogens. Vaccines produced this way are much higher quality, making them safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/news/next-generation-vaccine-production
  • Life Science job fair - 28/04/2021

    CONTACT2021

    Heidelberg
    https://www.bio-pro.de/en/events/past-events/contact2021
  • Freudenberg Filtration Technologies - 01/10/2020 Kfz-Innenraumfilter von Freudenberg Filtration Technologies scheiden zunächst Partikel und einen Großteil viraler Areosole ab und inaktivieren diese in ihrer letzten, mit Fruchtextrakten imprägnierten bio-funktionalen Schicht

    Coronavirus thwarted: with filters against aerosol spread

    Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.

    https://www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
  • Organ failure due to fatty liver - 24/09/2020 Drawing of a human torso with a liver in red.

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Event - 03/11/2020 AdobeStock_209291980.jpg

    Building a Sustainable Network for Smart SMEs in the Alpine Region

    Online event, Registration deadline: 16/10/2020
    https://www.bio-pro.de/en/events/past-events/building-sustainable-network-smart-smes-alpine-region
  • Mosses for pharmaceutical production - 16/09/2020 Eleva_Bild_1.jpg

    Factor H as a therapeutic option for viral diseases - including COVID-19

    The search for drug candidates for COVID-19 diseases is well underway. Factor H, which is part of the innate immune system, might also be a future therapeutic option. The Freiburg-based biotech company eleva has developed a technology for producing this human protein in moss cells. The active ingredient, which might also have a regulatory effect in other diseases, is currently undergoing preclinical testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/factor-h-therapeutic-option-viral-diseases-including-covid-19
  • Phytopharmaceuticals - 14/09/2020 Cannabisnet_Bild_11.jpg

    Medicinal cannabis to be grown in Germany

    Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
  • Biochip systems - 02/09/2020 Hand hält einen Fett-Chip (Organ-on-a-Chip) in die Kamera. Gut zu sehen sind die Kammern und Kapillaren auf dem Mikrofluidik-System.

    Miniature organs with great potential

    Dr. Peter Loskill and his team at the Fraunhofer Institute in Stuttgart and the University Hospital of Tübingen are developing what is known as an "organ-on-a-chip" (OoC). An OoC is a microfluidic system that simulates small functional units of organ tissue. OoCs can be used in different ways: in basic and pharmaceutical research as well as in clinical research and application, where they might render many animal experiments…

    https://www.gesundheitsindustrie-bw.de/en/article/news/miniature-organs-great-potential
  • Innovative Therapies - 20/08/2020 Das Bild zeigt eine pipettierende Frau in Nahaufnahme. Symbolbild für analytische Dienstleistungen des portraitierten Unternehmens.

    Labor Dr. Merk is fully committed to viral therapies

    Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

    https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
  • CeGat GmbH - 06/08/2020 Cegat_Teaser.jpg

    CeGaT: Specific coronavirus antibody test for all

    Have I perhaps already had COVID-19 in the past? This is a question many of us have been asking. Reliable tests that would provide the answer have simply not been available until now. However, the Tübingen-based biotech company CeGaT is now offering a coronavirus antibody test to anyone who wants one, thus answering this question with the highest probability currently possible. Response to the offer has been huge in the few weeks since the test…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-specific-coronavirus-antibody-test-all
  • Event - 26/08/2020 - 27/08/2020

    Global Cluster Partnering - Healthcare

    online
    https://www.bio-pro.de/en/events/past-events/global-cluster-partnering-healthcare
  • TGU Varimol - 24/07/2020 Das Bild zeigt zwei kleine braune Chemikalienfläschchen, die alle nötigen Reagenzien für ihre Anwendung für Kunden der Varimol enthalten.

    Click chemistry for new medical procedures

    Using a simple molecular click process, biochemists have been able to connect ring-shaped molecules with each other and couple therapeutically active substances to these molecules. Drugs can thus be specifically delivered to diseased cells and used for imaging processes or biosensors. The Stuttgart-based start-up Varimol is using this new technology to provide its customers with tailored applications that are as simple to use as a kit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/click-chemistry-new-medical-procedures
  • Microstructure Technology - 17/07/2020 eNase_Bild_4.jpg

    An electronic nose for many applications

    Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

    https://www.gesundheitsindustrie-bw.de/en/article/news/electronic-nose-many-applications
  • Stem cell therapy for regenerating intervertebral discs - 16/07/2020 800_Wisi_Focus_Web.jpg

    Ulm’s simulator has Europe’s back

    Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
  • Qualitative soil fertiliser - 10/07/2020 P2030384-2.jpg

    How natural cycles can be closed with wood ash

    Recycled material instead of waste: wood ash is good for soil and plants - if the quality is right. The German Federal Quality Association for Food Ash ensures reliable wood ash standards with its certifications. The RAL-Dünger label for fertilisers provides the necessary certification for natural wood ashes to be used in the circular economy.

    https://www.biooekonomie-bw.de/en/articles/news/how-natural-cycles-can-be-closed-wood-ash
  • Review article (new edition) - 08/07/2020 Arm in den mithilfe einer Spritze eine Impfung gespritzt wird.

    Immunology – at the forefront of medical progress

    Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/immunology-forefront-medical-progress

Page 35 / 48

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 48
  • eine Seite zurück
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • About us
    • Team
    • History and achievements
    • Supervisory Board
    • Career
    • Contact / Travel information
  • Activities
    • Start-up support
    • Cooperation initiatives
    • Anlaufstelle Regulatorik Gesundheitswirtschaft BW
  • Projects
    • Current projects
    • General Projects
    • Completed projects
  • Services
    • Funding
    • Research institutions
    • Healthcare industry database
    • Job market
    • Newsletter
    • Stay in touch with us!
  • Information
    • Press releases & contact
    • Publications
  • Events
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.bio-pro.de/en/search